These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24182320)

  • 1. Recent patents in the field of radioprotector development: opportunities and challenges.
    Suman S; Jain S; Chandna S
    Recent Pat Biotechnol; 2013 Dec; 7(3):219-27. PubMed ID: 24182320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical countermeasures for unwanted CBRN exposures: part II radiological and nuclear threats with review of recent countermeasure patents.
    Singh VK; Romaine PL; Newman VL; Seed TM
    Expert Opin Ther Pat; 2016 Dec; 26(12):1399-1408. PubMed ID: 27610458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation countermeasure agents: an update (2011-2014).
    Singh VK; Newman VL; Romaine PL; Wise SY; Seed TM
    Expert Opin Ther Pat; 2014 Nov; 24(11):1229-55. PubMed ID: 25315070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BIO 300: a promising radiation countermeasure under advanced development for acute radiation syndrome and the delayed effects of acute radiation exposure.
    Singh VK; Seed TM
    Expert Opin Investig Drugs; 2020 May; 29(5):429-441. PubMed ID: 32450051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status.
    Singh VK; Garcia M; Seed TM
    Int J Radiat Biol; 2017 Sep; 93(9):870-884. PubMed ID: 28657406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of amifostine for the acute radiation syndrome.
    Singh VK; Seed TM
    Expert Opin Drug Saf; 2019 Nov; 18(11):1077-1090. PubMed ID: 31526195
    [No Abstract]   [Full Text] [Related]  

  • 8. Radiation protective effects of baclofen predicted by a computational drug repurposing strategy.
    Ren L; Xie D; Li P; Qu X; Zhang X; Xing Y; Zhou P; Bo X; Zhou Z; Wang S
    Pharmacol Res; 2016 Nov; 113(Pt A):475-483. PubMed ID: 27664700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
    Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of biomarkers for assessing radiation injury and efficacy of countermeasures.
    Singh VK; Newman VL; Romaine PL; Hauer-Jensen M; Pollard HB
    Expert Rev Mol Diagn; 2016; 16(1):65-81. PubMed ID: 26568096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part III. Countermeasures under early stages of development along with 'standard of care' medicinal and procedures not requiring regulatory approval for use.
    Singh VK; Hanlon BK; Santiago PT; Seed TM
    Int J Radiat Biol; 2017 Sep; 93(9):885-906. PubMed ID: 28657400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioprotective Agents: Strategies and Translational Advances.
    Kamran MZ; Ranjan A; Kaur N; Sur S; Tandon V
    Med Res Rev; 2016 May; 36(3):461-93. PubMed ID: 26807693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute radiation syndrome drug discovery using organ-on-chip platforms.
    Singh VK; Seed TM
    Expert Opin Drug Discov; 2022 Aug; 17(8):865-878. PubMed ID: 35838021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures.
    Singh VK; Seed TM
    Int J Radiat Biol; 2017 Sep; 93(9):851-869. PubMed ID: 28650707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioprotectors in radiotherapy - advances in the potential application of phytochemicals.
    Szejk M; Kołodziejczyk-Czepas J; Żbikowska HM
    Postepy Hig Med Dosw (Online); 2016 Jun; 70(0):722-34. PubMed ID: 27356603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonhuman primates as models for the discovery and development of radiation countermeasures.
    Singh VK; Olabisi AO
    Expert Opin Drug Discov; 2017 Jul; 12(7):695-709. PubMed ID: 28441902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patents for critical pharmaceuticals: the AZT case.
    Ackiron E
    Am J Law Med; 1991; 17(1-2):145-80. PubMed ID: 1877607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.